Search

everythinglearnresearchcommunity

for

Search:↓

Women with PCOS often have hair loss, which is linked to acne or excess body hair but not to worse hormone or metabolic issues.

Insulin resistance is significantly linked to a higher risk of depression in women with PCOS.

The conclusion is that women under 35 should start fertility checks after 12 months of trying to conceive, women over 35 after 6 months, and women over 40 should start immediately. The checks should include ovulation status, reproductive tract structure, and male partner's semen evaluation.

Caucasian and Asian women with PCOS generally show similar symptoms, except Asian women have less chest hair.

Larger ovarian size is linked to higher insulin resistance in women with PCOS.

Hispanic women with PCOS are more likely to have liver diseases like NAFLD and NASH.

Older obese women with PCOS have higher cardiovascular and metabolic risks despite lower androgen levels.

Changing the diagnosis criteria for PCOS might miss women at risk for related health issues.

Early diagnosis and treatment of PCOS in young people is important to prevent long-term health problems.

The type of PCOS a woman has doesn't strongly predict her skin or metabolic symptoms; obesity is a more important factor.

Women with PCOS and higher BMI, especially those with morbid obesity, are at greater risk for depression.

Clinical signs of excess male hormones and actual hormone levels in the blood do not always match in women with polycystic ovary syndrome.

Hair loss is common in women with PCOS and is linked to symptoms like acne and excess hair but not to worse metabolic health.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Saw palmetto supplements may modestly improve hair regrowth with few side effects, but more research is needed.

Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.

Polycystic Ovary Syndrome should be seen mainly as a condition of excess male hormones, with a focus on this in its definition.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

The modified Ferriman-Gallwey method is a useful tool for diagnosing hirsutism.

Most women with PCOS have high levels of male hormones, and free testosterone is the best marker for this.

The document concludes that proper diagnosis and a multidisciplinary approach are crucial for managing Congenital Adrenal Hyperplasia effectively.

Too much male hormone is the main cause of Polycystic Ovary Syndrome.

Androgens block hair growth by disrupting cell signals; targeting GSK-3 may help treat hair loss.

Hair follicle regeneration needs special conditions and young cells.

Dermal papilla cells help wounds heal better and can potentially grow new hair.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.

Vitamin D3 analogs can promote hair growth in mice genetically prone to hair loss.